Released Mar 26, 2024, before the open
10-K filed Mar 26, 2024, 86 days after period end · 0001576885-24-000047
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$16.50M-$16.50M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$18,486,000N/M
Operating Cash Flowderived-$8,314,000N/M
Free Cash Flowderived-$8,328,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$16.50M | -$12.87M | -$8.35M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR